source
- Vertex drops mRNA cystic fibrosis program over 'tolerability' issuesVertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering th…Endpoints · 2mo ago↗ source
- STAT+: French regulator fines Novo and Lilly over weight loss ad campaignsFrance's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.STAT · 2mo ago↗ source
- Opinion: Mifepristone court ruling makes drug development riskier for everyoneThe 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.STAT · 2mo ago↗ source